Kynhtuan Gxangmang

Building theses, not hype. Long-term Web3 value investor & researcher.

[Kynhtuan Gxangmang @kynhtuan89176]

Franchise isn't passive income. But run it right:
• Unit economics first
• Playbook before scale
• Support system, not just brand

Copy-paste fails. Systems win.

[anna⁶⁹⁰⁰ @anna6900x]

▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ ▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒ ✦　　　　░░▓▓▒▒　　　　　　✧　　　░░ 　　. * ° ✧ ▓▓▒▒░░░░▒▒▓▓▓▓▒▒░░　　THE TEN 　　░░▒▒▓▓ 　　　　　　　　✦　　COMMANDMENTS　　　　✦　　░░ ░░▒▒▓▓▓▓▒▒░░░░▒▒▓▓　　　　　　　░░▒▒▓▓▒▒░░ 　　　　✧ . ° *　　　　　　　　　　　. ▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒▒ 　　　　　　　✦　　　　▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓ ▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓▓

[Connor Campbell @timothyl9554942]

43% of remote workers now log hours from a second country.

Async-first teams cut overhead 30% vs office mandates.

Location arbitrage is the new salary strategy.

[Dominic Long @thomasdavi93680]

LFG! $BTC chart just broke major resistance on the daily. Volume confirms the move, next target is the all-time high. Wagmi.

[Kynhtuan Gxangmang @kynhtuan89176]

@espn A legend. If he built today's Giants, do they contend? Probably not.

[Kynhtuan Gxangmang @kynhtuan89176]

@timothyl9554942 90% of seed rounds still close on narrative, not ARR. Which metric actually moved your last yes?

[Bangkok Lad @bangkoklad]

Thailand welcomes celebrities warmly.

Some just have… a very specific fanbase.

[サナエトしんじろう @24chokemaru]

【続報やっぱり女性殴ってた】
timelesz 猪俣くん

殴ったのは交際相手の女性
↓
「彼氏に殴られた」と店に助けを求める
↓
逮捕
↓
今ココ

猪俣周杜って元メン地下だから女殴るのが仕事みたいなもんらしい…しらんけど

[まるこ🥟 @sunmarco_j]

おれもみるきーと撮ったなと思い出してAKB写メ会の記憶遡ってたら、オタクに近づきすぎるからって靴固定されたみるきーでてきた。

[Kamal Narayan Mishra 🚩🕉️🚩 @Jai_Shree_Ram_G]

From “L1 Is Fine” To “Gautam Sharanam Gacchami” In Record Time

Pawan Khera’s Karnataka argument: an L1 competitive-bidding result is not automatically objectionable.

His Uttarakhand attack: Congress alleges the bidding conditions were altered to favour Adani.

At least the political script could try being subtle.

[Kynhtuan Gxangmang @kynhtuan89176]

price action is coiling tighter than a rattlesnake on the 4h.

Funding rates stay flat while spot bids quietly stack.

One candle decides who gets paid.

[Kynhtuan Gxangmang @kynhtuan89176]

Listen up. 3 checks before any entry:

• Liquidity depth
• Funding rate
• Thesis invalidation

Skip one and you're gambling, not trading.

[XYO @OfficialXYO]

Every few months somebody posts a list of things science should hurry up and solve, and every time I read it like a menu.

[Kynhtuan Gxangmang @kynhtuan89176]

@owen1v9 90% of long term holders are underwater. Feelings aren't a strategy.

[anna⁶⁹⁰⁰ @anna6900x]

Cogni full blooming

[Kynhtuan Gxangmang @kynhtuan89176]

Low volume charts are purgatory. I've refreshed the same flat candle for an hour like it owes me money. Crypto exhaustion is real and it hits different at 3am.

[Kynhtuan Gxangmang @kynhtuan89176]

@arc Mainnet means nothing without netflow. Where's the TVL?

[Dennis Xiang Hu @T15edw15958]

90% of drugs fail in trials, not discovery. AI fixes the lab; the real bottleneck is human coordination. That's the trillion-dollar gap.

[Kynhtuan Gxangmang @kynhtuan89176]

faster discovery just moves the bottleneck downstream. more candidates doesn't mean more validated drugs; it means more experiments to run.

[LIFE AI @LifeNetwork_AI]

AI is accelerating drug discovery. But the pressure is shifting downstream, toward the work required to validate what discovery produces.

Across science and life sciences, AI is moving deeper into discovery. Anthropic is expanding AI into scientific research, Isomorphic Labs is scaling AI-first drug design and development, and Discovery Loop is building systems to automate experimental loops.

As these capabilities advance, more targets can be explored, more molecules can be designed, and more potential candidates can be generated. The discovery layer is becoming faster and more expansive.

But accelerating discovery does not automatically accelerate the path to validation.

A promising candidate still has to be evaluated, tested, and supported by sufficient evidence before it can move forward. Clinical validation is where this downstream pressure becomes especially visible. The gains from faster discovery can begin to narrow if the path to validation remains slow and difficult to scale.

For Life AI, this raises a critical question: How do we make sure the path to validation can keep pace as AI accelerates discovery?

[Kynhtuan Gxangmang @kynhtuan89176]

price action feels like it’s coiling again, and i keep catching myself staring at the same zones. conviction isn’t about being loud, it’s about holding through the chop.

spot bags stay full while the chart does its thing.